trending Market Intelligence /marketintelligence/en/news-insights/trending/j2LhEJFJxrGNP2rIkjax8w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

US FDA extends review of Flexion's osteoarthritis knee pain drug Zilretta

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

US FDA extends review of Flexion's osteoarthritis knee pain drug Zilretta

The U.S. Food and Drug Administration needs more time to review Flexion Therapeutics Inc.'s supplemental new drug application for Zilretta beyond the expected Oct. 14 decision date.

Zilretta was approved to treat osteoarthritis knee pain in 2017. The Burlington, Mass.-based biotechnology company has asked the FDA to revise Zilretta's label to include results from a Phase 3b clinical trial that evaluated repeated doses of the drug in patients with osteoarthritis knee pain.

The regulator did not provide a new date for the decision, but said the review is expected to be completed in the next few weeks, according to Flexion's Oct. 14 press release. Flexion also said the agency has not asked for any additional information to supplement the application.

Flexion develops anti-inflammatory and pain management therapies for patients with musculoskeletal conditions.